2024 Neuromuscular Summit

Time: 5:00 PM - 6:00 PM ET

Currently, there is no cure for SMA, although this may change with expanding treatment options. A rapidly changing treatment landscape is altering the clinical management of patients with SMA. Three therapies are currently FDA-approved and have dramatically impacted this condition. However, many health needs remain unmet in this patient population. As evidence of therapeutic effects continues to emerge, it is important for clinicians to be aware of evolving patient needs and strategies that can facilitate earlier diagnosis and more effective disease management. Furthermore, incorporating principles of diversity, equity, and inclusion (DEI) into SMA management is crucial to addressing disparities in healthcare outcomes among minority groups. By focusing on these areas, healthcare systems can better support the diverse needs of all SMA patients, fostering a more inclusive approach to care. Thus, this activity will feature expert discussing the assessment of bulbar function, use of novel therapies, and best practices for SMA management with a focus on minority patients.

Time: 6:00 PM - 7:00 PM ET

Many people with MG have difficulty controlling their condition and experience worsening of symptoms even with pharmacologic therapy. Additionally, long-term side effects frequently limit drug therapy use. Treatment challenges can be even more pronounced in certain subpopulations of individuals with MG, such as pregnant women and children.

This activity will feature clinical experts discussing the supporting data and rationale underpinning best management practices for managing pregnant women and children with MG. It will employ a case based approach to illustrate real-world patient encounters that require astute and timely clinical decision making. Insights shared will help you improve the care of your patients with MG.

Time: 7:00 PM - 8:00 PM ET

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare chronic disorder affecting peripheral nerves and nerve roots for which there are several unmet needs. More than half of patients with CIDP do not consider their current disease burden to be satisfactory. This is linked, in part to the fact that clinicians have suboptimal knowledge EAN/PAN guidelines and my not be accessing the latest information about emerging biologic treatments for CIDP. CME is warranted to address these gaps. Thus, this activity will feature clinical experts discussing current guidelines and data supporting best practices for managing CIDP. It will feature an animated video highlighting the disease pathophysiology and commentary about selection of therapy, including best practices for use of newly approved therapy.

Child Neurologist
Children's Hospital of Philadelphia
Associate Professor of Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Clinical Associate Professor of Neurology and Neurological Sciences
Division of Neuromuscular Medicine
Interim Vice Chair; Diversity, Equity, and Inclusion; Neurology Department
Well-Being Director, Neurology Department
Stanford University Hospital
Palo Alto, CA

Clinical Professor, Department of Pediatrics
Clinical Professor, Department of Neurology
Professor Emeritus of Pediatrics and Neurology, Department of Pediatrics

Associate Professor of Neurology
Duke University School of Medicine
Durham, NC

Assistant Professor
Department of Pediatrics
University of Florida
Gainesville, FL